Dr. Hegde is the VP and Chief Scientific Officer, Global Laboratory Services. She joined PerkinElmer on October 1, 2016. The focus of her clinical work is the development and implementation of high-throughput next generation sequencing (NGS) strategies for genomic disorders using sequence capture technologies, robotics, clinical exome and genome sequencing, and oligonucleotide array platforms. Read her full bio.

Interview with Madhuri Hegde, Vice President and Chief Science Officer of PerkinElmer’s Global Laboratory Services

Q: What need is Global Laboratory Services addressing?

A: PerkinElmer Genomics is global (genomics) laboratory service with laboratories in US, India and China, addressing genetic/genomic testing across the globe. Although the prevalence of, and access to, genomic testing has been increasing rapidly in the United States over the past decade, this is not necessarily the case in other parts of the world. PerkinElmer Genomics aims to offer genetic testing in some of these underserved communities in order to increase access. Additionally, our global laboratory service will also increase the scientific communities’ understanding of genetic variation and underpinnings of genomic disease in these understudied populations.

Q: What are the products and/or services Global Laboratory Services offers/develops to address this need? What makes Global Laboratory Services unique?

A: PerkinElmer Genomics offers an unmatched continuum of care for its patients – from newborn screening all the way through whole genome sequencing (WGS), and almost everything in between, paired with biochemical testing.We are the only laboratory in the world that has validated all of our testing (including WGS) on dried blood samples, affording us the ability to offer simple sample collections to patients around the world.

In our flagship laboratory in the United States, we have leveraged the NGS workflow solutions and automation tools offered by PerkinElmer to build a unique genomics laboratory with unmatched efficiency and sustainability. Combined with our optimized testing workflows and our proprietary high-throughput interpretation platform (ODIN),we are able to introduce and offer affordable testing to all patients who can benefit. Furthermore, with strategic investments in laboratories across the world, we plan to create a genomic testing network that will allow us introduce our superior testing services to previously underserved markets.

Q: What is your role at Global Laboratory Services and what excites you about your work?

A: My current role is Vice President and Chief Scientific Officer of PerkinElmer’s Global Laboratory Services. In this role I oversee all genomic testing services at both PerkinElmer Genomics and other genetic laboratories owned and operated by PerkinElmer. Additionally, I play an active role in assessing new assays and technologies for our global laboratory network, as well as participating in setting the PerkinElmer strategic roadmap for the coming years.

I think the thing that makes me the most excited about my role is really the ability to positively influence the genomics landscape by making testing more affordable and accessible to patients. I am also grateful to be in a position that gives me exposure and allows me to bring new and innovative technologies to the market to both further the genomics and overall healthcare landscape.

Q: When thinking about Global Laboratory Services and the domain Global Laboratory Services is working in, what are some of the recent breakthroughs that are propelling the field forward and how will they impact healthcare?

A: There are several things that are currently propelling the field of genomics forward, including the reduction in the cost of sequencing, coupled with the ability to simply sequence more information faster than ever before. Ten years ago we were limited in the amount of sequencing that we could perform due to the inherit limitations of Sanger sequencing. Today, we can we sequence an entire genome at the same price as a panel ten years ago, and potentially with a shorter turn-around-time. This significant improvement in sheer sequencing power is propelling the field forward by leaps and bounds with regards to understanding genetic components of disease.

Another item that is propelling the field forward is the implementation of new technologies to aid in data aggregation and variant interpretation. In fact, our laboratory has recently developed proprietary data analysis software, ODIN (Ordered Data Interpretation Network), that does just that. ODIN allows my team to quickly exchange and view information while interpreting genomic data, and also aggregate the testing data from across our global network of laboratories. We are also looking beyond DNA sequencing into RNA sequencing and metabolomics through some strategic partnerships.

Q: What are the short-term challenges that Global Laboratory Services and its peers are facing?

A: One of the main challenges of running a global network of genomic laboratories is maintaining consistent and constant communication across all of the sites, as well as data integration for interpretation and reporting. Everyone is working extremely hard to deliver superior genomic testing results to all of our patients across the globe, but finding that time to break away that important work is essential to maintain seamless operational workflows. Recently we have appointed a new Global Director of Laboratory Operations to ensure that our communication is continual, and I feel like this will only enhance our already thriving global network of genomic laboratories. Other than that, challenges around translating “ precision medicine / evidence based medicine” to a more granular and grass roots level is what most quality laboratories are trying to achieve, which in turn is driving innovation in genomics.

Interview with Ralph Snyderman from Duke University

Q: What research are you or your lab focusing on and why, and what problem(s) are you trying to solve?

A: My work involves designing, implementing and studying innovations in medical education that allow our medical schools to fulfill our social contract to improve the health of our communities and reduce the suffering of our patients.

Read More

Interview with Catherine Reinis Lucey from UCSF

Q: What research are you or your lab focusing on and why, and what problem(s) are you trying to solve?

A: My work involves designing, implementing and studying innovations in medical education that allow our medical schools to fulfill our social contract to improve the health of our communities and reduce the suffering of our patients.

Read More

Interview with Gunnar Carlsson from Ayasdi

Q: What need is Ayasdi addressing?

A: Ayasdi is pioneering the application of artificial intelligence to value-based care by targeting two of the most complex problems in healthcare: population risk stratification and clinical variation management.

Read More

Interview with Nikole Kimes from Siolta Therapeutics

Q: What need is Siolta Therapeutics addressing?

A: Chronic diseases, including inflammatory diseases such as asthma, now represent the leading cause of mortality and morbidity worldwide.

Read More

Note from Dr. Patrick Conway, President & CEO, Blue Cross and Blue Shield NC to PMWC

VC activity is booming in healthcare, with second quarter drawing in $5.1 billion in capital. That is 22% of the total $23 billion raised by all VC-based companies in the U.S., according to latest Pricewaterhouse Coopers quarterly report.

Read More

Interview with Atul Sharan, Co-founder and CEO, CellMax Life

Q: CellMax has developed non-invasive blood tests based on Circulating tumor cells CTC. How do you see these tests being adopted clinically?

A: Survival rates are greater than 90% for cancers that are detected at an early stage.

Read More

Interview with Wendell Jones from Q² Solutions | EA Genomics

Q: What need is Q² Solutions | EA Genomics addressing?

A: As a leading provider of genomic services in clinical trials and discovery, Q² Solutions | EA Genomics advances science by harnessing technological expertise to drive understanding of the human genome and disease biology to detect the effects of therapies.

Read More

Interview with Ben Solomon from GeneDx

Q: What need is GeneDx addressing?

A: GeneDx was started in 2000 by two NIH scientists with the mission of making genetic testing accessible for patients with rare diseases.

Read More

Interview with Ty Ridenour from RTI International

Q: What need is RTI International addressing?

A: As an independent research institute, RTI is dedicated to improving the human condition. We answer questions that demand an objective and multidisciplinary approach—one that integrates expertise across the social and laboratory sciences, engineering, and international development.

Read More

Interview with Madhuri Hegde, Vice President and Chief Science Officer of PerkinElmer’s Global Laboratory Services

Q: What need is Global Laboratory Services addressing?

A: PerkinElmer Genomics is global (genomics) laboratory service with laboratories in US, India and China, addressing genetic/genomic testing across the globe.

Read More

Interview with Rita R. Colwell from University of Maryland College Park and John Hopkins School of Public Health

Q: What research are you or your lab focusing on and why, and what problem(s) are you trying to solve?

A: The research that I am focusing on is understanding the microbiome of the human system and the environment, which means understanding the gut flora and its relationship to health and disease.

Read More

Interview with Dr. Nicholas Dracopoli from Personal Genome Diagnostics

Q: What need is Personal Genome Diagnostics (PGDx) addressing?

A: PGDx is developing standardized, clinical Next Generation Sequencing (NGS) kits to help enable effective treatment decisions for cancer patients.

Read More

Interview with Mohsen Hejrati from Clusterone

Q: What need is Clusterone addressing?

A: AI and machine learning are becoming cornerstone technologies for scientists and engineers, but access to these technologies is still cumbersome.

Read More

VC Investment in Precision Medicine Boomed in Q2 Mega-deals Hitting Record Levels

VC activity is booming in healthcare, with second quarter drawing in $5.1 billion in capital. That is 22% of the total $23 billion raised by all VC-based companies in the U.S., according to latest Pricewaterhouse Coopers quarterly report.

Read More

Interview with Patrick Conway from Blue Cross and Blue Shield of North Carolina

Q: In the past, you served as director of the Center for Medicare and Medicaid Innovation. What are you most proud of accomplishing at CMMI?

A: During my tenure at the Centers for Medicare and Medicaid Services, one of my many roles included serving as the Director of the Center for Medicare and Medicaid Innovation.

Read More
University of Michigan

The Precision Medicine World Conference (PMWC), held annually in Silicon Valley, is coming back to North Carolina for its 2nd Conference back at Duke University on September 24-25, 2018.

PMWC 2018 Duke, the 15th installment of the conference, will spotlight the explosion of biomedical technologies, driving initiatives that enable the translation of precision medicine into direct improvements in health care.

 

  • Track 1 will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
    • Digital Phenotyping
    • Precision Public Health
    • Pharmacogenomics
    • The Microbiome
    • Rare Disease Diagnosis
    • Digital Health/Health and Wellness
    • Early Days of Life Sequencing
    • Diversity in Precision Medicine
    • Resilience
    • AI and Machine Learning
    • Gene Editing
    • Large Scale Bio-data Resources to Support Drug Development (PPPs)
    • Point-of Care Dx Platform
    • FDA Efforts to Accelerate PM
    • Implementation into Health Care Delivery
    • Next Gen. Workforce of PM
    • Immunotherapy
    • Robust Clinical Decision Support Tools
    • Creating Clinical Value with Liquid Biopsy ctDNA, etc.
    • Neoantigens
    • Emerging Technologies In PM

The Precision Medicine World Conference (PMWC), held annually in Silicon Valley, is coming back to North Carolina for its 2nd Conference back at Duke University on September 24-25, 2018.

PMWC 2018 Duke, the 15th installment of the conference, will spotlight the explosion of biomedical technologies, driving initiatives that enable the translation of precision medicine into direct improvements in health care.

 

    • Track 1 will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
      • Digital Phenotyping
      • Precision Public Health
      • Pharmacogenomics
      • The Microbiome
      • Rare Disease Diagnosis
      • Digital Health/Health and Wellness
      • Early Days of Life Sequencing
      • Diversity in Precision Medicine
      • Resilience
      • AI and Machine Learning
      • Gene Editing
      • Large Scale Bio-data Resources
        to Support Drug Development (PPPs)
      • Point-of Care Dx Platform
      • FDA Efforts to Accelerate PM
      • Implementation into Health Care Delivery
      • Next Gen. Workforce of PM
      • Immunotherapy
      • Robust Clinical Decision Support Tools
      • Creating Clinical Value with Liquid Biopsy
        ctDNA, etc.
      • Neoantigens
      • Emerging Technologies In PM
  • Track 2- PMWC 2018 Duke Showcase, will enable 15-minute company presentations on latest novel technologies. Apply to present here.
big data diagnostics session

Clinical Dx Showcase

crispr showcase

Emerging Therapeutics Showcase

NGS Showcase

Genomic Profiling Showcase

AI Showcase Session Image

AI and Data Sciences Showcase

  • Luminary and Pioneer Awards, honoring individuals who contributed, and continue to contribute, to the field of Precision Medicine
  • 500+ multidisciplinary attendees, from across the entire spectrum of healthcare, representing different types of companies, technologies, and medical centers with leadership roles in precision medicine

[chimpy_lite_form]

pmwc-newsletter-img

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To recieve the lastest news and updates from the field, subscribe to the newsletter here.

You have Successfully Subscribed!